153 related articles for article (PubMed ID: 24038143)
21. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
Wikström P; Marusic J; Stattin P; Bergh A
Prostate; 2009 Jun; 69(8):799-809. PubMed ID: 19189305
[TBL] [Abstract][Full Text] [Related]
22. Transcript levels of androgen receptor variant AR-V1 or AR-V7 do not predict recurrence in patients with prostate cancer at indeterminate risk for progression.
Zhao H; Coram MA; Nolley R; Reese SW; Young SR; Peehl DM
J Urol; 2012 Dec; 188(6):2158-64. PubMed ID: 23088973
[TBL] [Abstract][Full Text] [Related]
23. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
[TBL] [Abstract][Full Text] [Related]
24. Interrogating androgen receptor function in recurrent prostate cancer.
Zhang L; Johnson M; Le KH; Sato M; Ilagan R; Iyer M; Gambhir SS; Wu L; Carey M
Cancer Res; 2003 Aug; 63(15):4552-60. PubMed ID: 12907631
[TBL] [Abstract][Full Text] [Related]
25. Expression screening of cancer/testis genes in prostate cancer identifies NR6A1 as a novel marker of disease progression and aggressiveness.
Mathieu R; Evrard B; Fromont G; Rioux-Leclercq N; Godet J; Cathelineau X; Guillé F; Primig M; Chalmel F
Prostate; 2013 Jul; 73(10):1103-14. PubMed ID: 23532770
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
Wikström P; Lindahl C; Bergh A
Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
[TBL] [Abstract][Full Text] [Related]
27. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
Mellado B; Marin Aguilera M; Pereira MV
Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
[TBL] [Abstract][Full Text] [Related]
28. Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.
Shiota M; Yokomizo A; Naito S
Free Radic Biol Med; 2011 Oct; 51(7):1320-8. PubMed ID: 21820046
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
30. Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.
Stoyanova T; Riedinger M; Lin S; Faltermeier CM; Smith BA; Zhang KX; Going CC; Goldstein AS; Lee JK; Drake JM; Rice MA; Hsu EC; Nowroozizadeh B; Castor B; Orellana SY; Blum SM; Cheng D; Pienta KJ; Reiter RE; Pitteri SJ; Huang J; Witte ON
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6457-E6466. PubMed ID: 27694579
[TBL] [Abstract][Full Text] [Related]
31. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
[TBL] [Abstract][Full Text] [Related]
32. SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate Cancer.
Zhang X; Coleman IM; Brown LG; True LD; Kollath L; Lucas JM; Lam HM; Dumpit R; Corey E; Chéry L; Lakely B; Higano CS; Montgomery B; Roudier M; Lange PH; Nelson PS; Vessella RL; Morrissey C
Clin Cancer Res; 2015 Oct; 21(20):4698-708. PubMed ID: 26071481
[TBL] [Abstract][Full Text] [Related]
33. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions.
Tilki D; Evans CP
Can J Urol; 2014 Apr; 21(2 Supp 1):7-13. PubMed ID: 24775718
[TBL] [Abstract][Full Text] [Related]
34. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
[TBL] [Abstract][Full Text] [Related]
35. The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.
O'Hurley G; Prencipe M; Lundon D; O'Neill A; Boyce S; O'Grady A; Gallagher WM; Morrissey C; Kay EW; Watson RW
Prostate; 2014 Feb; 74(3):306-13. PubMed ID: 24249383
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
Taplin ME
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Castration-Resistant Prostate Cancer with Androgen Receptor-Axis Imaging.
Pandit-Taskar N; Veach DR; Fox JJ; Scher HI; Morris MJ; Larson SM
J Nucl Med; 2016 Oct; 57(Suppl 3):73S-78S. PubMed ID: 27694177
[TBL] [Abstract][Full Text] [Related]
38. Regulation of SPDEF expression by DNA methylation in advanced prostate cancer.
Vatanmakanian M; Steffan JJ; Koul S; Ochoa AC; Chaturvedi LS; Koul HK
Front Endocrinol (Lausanne); 2023; 14():1156120. PubMed ID: 37900138
[TBL] [Abstract][Full Text] [Related]
39. The hallmarks of castration-resistant prostate cancers.
Katsogiannou M; Ziouziou H; Karaki S; Andrieu C; Henry de Villeneuve M; Rocchi P
Cancer Treat Rev; 2015 Jul; 41(7):588-97. PubMed ID: 25981454
[TBL] [Abstract][Full Text] [Related]
40. [Current status of castration resistant prostate cancer basic research].
Sakamoto S; Ichikawa T
Nihon Rinsho; 2014 Dec; 72(12):2097-102. PubMed ID: 25518340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]